{"organizations": [], "uuid": "eb0bc113c00442d2818208819fba96c248b5f172", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180208.html", "section_title": "Archive News &amp; Video for Thursday, 08 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/gilead-sciences-fda/corrected-u-s-fda-approves-gileads-three-drug-hiv-regimen-idUSL4N1PX6E5", "country": "US", "domain_rank": 408, "title": "CORRECTED-U.S. FDA approves Gilead's three-drug HIV regimen", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.159, "site_type": "news", "published": "2018-02-08T05:46:00.000+02:00", "replies_count": 0, "uuid": "eb0bc113c00442d2818208819fba96c248b5f172"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/gilead-sciences-fda/corrected-u-s-fda-approves-gileads-three-drug-hiv-regimen-idUSL4N1PX6E5", "ord_in_thread": 0, "title": "CORRECTED-U.S. FDA approves Gilead's three-drug HIV regimen", "locations": [], "entities": {"persons": [{"name": "akankshita mukhopadhyay", "sentiment": "none"}, {"name": "biktarvy", "sentiment": "none"}, {"name": "sriraj kalluvila", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "gilead", "sentiment": "negative"}, {"name": "glaxosmithkline", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "gilead sciences inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Corrects to remove reference to “bictegravir” as a previously approved drug)\nFeb 7 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences Inc’s three-drug regimen to treat HIV-1 infection.\nThe treatment, Biktarvy, is a once-daily tablet that combines two previously approved drugs - emtricitabine, tenofovir alafenamide and a new integrase inhibitor bictegravir, the company said.\nIt is available to patients who have been on a stable regimen for at least three months.\nBiktarvy has a boxed warning about the risk of post-treatment acute increase of hepatitis B.\nThe approval puts GlaxoSmithKline’s HIV businesses under threat as the company has been facing slowing demand and new competition.\nGilead’s shares were up 3.45 percent at $83.16 in afternoon trading on Wednesday. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Sriraj Kalluvila)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-08T05:46:00.000+02:00", "crawled": "2018-02-09T06:01:57.012+02:00", "highlightTitle": ""}